Iovance Biotherapeutics (IOVA) Capital Expenditures (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Capital Expenditures for 14 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 6.39% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $34.2 million (up 161.14% YoY), while the FY2025 annual figure was $33.8 million, up 205.68% from the prior year.
• Capital Expenditures retreated to $6.6 million in Q1 2026 per IOVA's latest filing, from $9.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $11.4 million in Q1 2022 and bottomed at $442000.0 in Q2 2024.
• Historically, Capital Expenditures has averaged $5.5 million across 5 years, with a median of $4.6 million in 2022.
• Annual changes were most pronounced in 2024 — Capital Expenditures plunged 95.36% — and 2025, when it surged 1588.01%.
• Iovance Biotherapeutics' Capital Expenditures stood at $3.0 million in 2022, then grew by 16.78% to $3.5 million in 2023, then gained by 18.11% to $4.2 million in 2024, then jumped by 123.61% to $9.3 million in 2025, then fell by 29.1% to $6.6 million in 2026.
• Business Quant data shows IOVA's Capital Expenditures at $6.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.8 million in Q3 2025.